@article {7564,
	title = {Docetaxel and intermittent erlotinib in patients with metastatic non-small cell lung cancer; a phase II study from the hellenic cooperative oncology group},
	journal = {Anticancer Research},
	volume = {34},
	year = {2014},
	note = {Cited By :2Export Date: 21 February 2017},
	month = {2014},
	pages = {5649 - 5655},
	abstract = {Aim: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). Patients and Methods: Patients were randomized to receive daily erlotinib for 12 consecutive days prior to docetaxel (Arm A) or after docetaxel (Arm B). Progression-free survival (PFS) was the primary end-point; secondary end-points were overall survival (OS) and objective response rate (ORR). Results: Fifty eligible patients received a total of 226 treatment cycles (median: 3). Median PFS and OS were 3.6 months and 10.5 months, respectively (differences were not statistically significant between the two arms). Neutropenia grade 3 and 4 occurred in 15 patients, while two patients developed grade 3 diarrhea. There were two treatment-related deaths (pulmonary embolism and non-neutropenic sepsis). Conclusion: Intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. {\textcopyright} 2014, International Institute of Anticancer Research. All rights reserved.},
	keywords = {Docetaxel, Erlotinib, Non-small cell lung cancer},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84917672306\&partnerID=40\&md5=5c448bd13ceb79b973d2fd6dac076e5b},
	author = {Karavasilis, V. and Kosmidis, P. and Syrigos, K.N. and Mavropoulou, P. and Dimopoulos, M.A. and Kotoula, V. and Pectasides, D. and Boukovinas, I. and Klouvas, G. and Kalogera-Fountzila, A. and Papandreou, C.N. and Fountzilas, G. and Briasoulis, E.}
}
